Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Libby's H*O*P*E*

Libby's H*O*P*E*

Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education). To learn more go to
UConn Researchers Develop Personalized Ovarian Cancer Vaccines. ...... | UConn Today -
New test can help doctors choose best treatment for ovarian cancer. .... -
Comparison of Pure and Mixed-Type Clear Cell Carcinoma of the Ovary: A Clinicopathological Analysis of 341 Chinese Patients. ....... [Int J Gynecol Cancer. 2014] - PubMed - NCBI -
Carcinosarcomas in female genital tracts: general review... [Bull Cancer. 2014 Jul-Aug] - PubMed - NCBI -
Malignant transformations in ovarian teratomas: a report of four cases.... [J Pak Med Assoc. 2014] - PubMed - NCBI -
Vitamin D Suppresses Leptin Stimulation of Cancer Growth through MicroRNA. ...... [Cancer Res. 2014] - PubMed - NCBI -
SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. ... [Mol Cancer Ther. 2014] - PubMed - NCBI -
These results support the clinical evaluation of SGN-LIV1A as a novel therapeutic agent for patients with LIV-1 expressing cancer, including breast, prostate, ovarian and uterine cancers, as well as melanoma). - Libby's H*O*P*E*
Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer.... [J Oncol. 2014] - PubMed - NCBI -
Single institution study found that decreasing stage at detection from Stage IIIC to stage IIIA epithelial ovarian cancer is associated with a 5-year survival advantage of nearly 20% in patients treated by surgical tumor cytoreduction and platinum-based chemotherapy. - Libby's H*O*P*E*
Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer: A Phase II Study.... [Int J Gynecol Cancer. 2014] - PubMed - NCBI -
Mechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Both In Vitro and In Vivo.... [PLoS One. 2014] - PubMed - NCBI -
Ovarian cancer oncogene FAL1 found in 'junk DNA'. ...... - ONA -
A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. ......: Cancer Cell -
Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High Rate of Complications. .... | Ovarian Cancer Research Fund -
Stanford licenses promising cancer drug to local biotech startup. .... - SFGate -
Mercy Medical Center Announces Opening of New Lya Segall Ovarian Cancer Institute. ... -
Mercy To Open New Ovarian Cancer Institute. .... - Dr. Rosenshein - Baltimore, Maryland -
Keck Medicine of USC researchers discover dual purpose of cancer drug in regulating expression of genes. .....Detail -
Penn Researchers Explain How Ends of Chromosomes are Maintained for Cancer Cell Immortality. ..... -
Effect of Ultrasound Sonication on Clonogenic Survival and Mitochondria of Ovarian Cancer Cells in the Presence of Methylene Blue. ...... -
Simple blood test could be used as tool for early cancer diagnosis. ...... Bristol University | News | September: -
Chemists recruit anthrax to deliver cancer drugs -- With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs. ...... | MIT News Office -
A Way to Kill Chemo-Resistant Ovarian Cancer Cells: Cut Down Their Protector -
How Can Women Reduce Their Risk of Ovarian Cancer? .....- YouTube -
Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. ..... [Int J Oncol. 2014] - PubMed - NCBI -
The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. ...... [Mod Pathol. 2014] - PubMed - NCBI -
Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review. ..... [Wien Med Wochenschr. 2014] - PubMed - NCBI -
An anti-mesothelin-monomethyl auristatin E conjugate with potent anti-tumor activity in ovarian, pancreatic and mesothelioma models. ....... [Mol Cancer Ther. 2014] - PubMed - NCBI -
A Transformational Journey Through Birth and Death. ......[Am J Nurs. 2014] - PubMed - NCBI -
ESMO 2014: TRACON Pharma to announce results from clinical trials of TRC105 (endoglin inhibitor) in patients with ovarian cancer to be presented at the 2014 Annual Meeting of the European Society for Medical Oncology. ...... - FirstWord Pharma -
Bacterial “Communication System” Could Be Used to Stop Spreading and Kill Cancer Cells, MU Study Finds. ...... -
Other ways to read this feed:Feed readerFacebook